These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
377 related articles for article (PubMed ID: 10985895)
1. High-dose platinum versus standard dose in advanced ovarian carcinoma: a randomized trial from the Gynecologic Cooperative Group of the French Comprehensive Cancer Centers (FNCLCC). Joly F; Héron JF; Kerbrat P; Chauvergne J; Rios M; Mayer F; Chinet-Charrot P; Goupil A; Lebrun-Jezekova D; Vennin D; Lhommé C; Macé-Lesec'h J; Crouet H Gynecol Oncol; 2000 Sep; 78(3 Pt 1):361-8. PubMed ID: 10985895 [TBL] [Abstract][Full Text] [Related]
2. Randomized phase III trial of topotecan following carboplatin and paclitaxel in first-line treatment of advanced ovarian cancer: a gynecologic cancer intergroup trial of the AGO-OVAR and GINECO. Pfisterer J; Weber B; Reuss A; Kimmig R; du Bois A; Wagner U; Bourgeois H; Meier W; Costa S; Blohmer JU; Lortholary A; Olbricht S; Stähle A; Jackisch C; Hardy-Bessard AC; Möbus V; Quaas J; Richter B; Schröder W; Geay JF; Lück HJ; Kuhn W; Meden H; Nitz U; Pujade-Lauraine E; ; J Natl Cancer Inst; 2006 Aug; 98(15):1036-45. PubMed ID: 16882940 [TBL] [Abstract][Full Text] [Related]
3. Dose intensive combination platinum and cyclophosphamide in the treatment of patients with advanced untreated epithelial ovarian cancer. Shapiro JD; Rothenberg ML; Sarosy GA; Steinberg SM; Adamo DO; Reed E; Ozols RF; Kohn EC Cancer; 1998 Nov; 83(9):1980-8. PubMed ID: 9806657 [TBL] [Abstract][Full Text] [Related]
4. Randomized trial of initial therapy with melphalan versus cisplatin-based combination chemotherapy in patients with advanced ovarian carcinoma: initial and long term results--Eastern Cooperative Oncology Group Study E2878. Wadler S; Yeap B; Vogl S; Carbone P Cancer; 1996 Feb; 77(4):733-42. PubMed ID: 8616766 [TBL] [Abstract][Full Text] [Related]
5. [Importance of platinum dose intensity in treatment of epithelial ovarian cancer. Austrian Study Group for Therapy of Ovarian Cancer]. Sevelda P; Kurz C; Obermair A; Vavra N; Breitenecker G; Czerwenka K; Dittrich C; Salzer H Wien Klin Wochenschr; 1993; 105(24):732-6. PubMed ID: 8116312 [TBL] [Abstract][Full Text] [Related]
6. Intraperitoneal versus intravenous cisplatin in combination with intravenous cyclophosphamide and epidoxorubicin in optimally cytoreduced advanced epithelial ovarian cancer: a randomized trial of the Gruppo Oncologico Nord-Ovest. Gadducci A; Carnino F; Chiara S; Brunetti I; Tanganelli L; Romanini A; Bruzzone M; Conte PF Gynecol Oncol; 2000 Feb; 76(2):157-62. PubMed ID: 10637064 [TBL] [Abstract][Full Text] [Related]
7. ICON 2 and ICON 3 data in previously untreated ovarian cancer: results to date. Harper P Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-23-S15-25. PubMed ID: 9346217 [TBL] [Abstract][Full Text] [Related]
8. Chemotherapy in advanced ovarian carcinoma: current standards of care based on randomized trials. Thigpen T; Vance R; Puneky L; Khansur T Gynecol Oncol; 1994 Dec; 55(3 Pt 2):S97-107. PubMed ID: 7835816 [TBL] [Abstract][Full Text] [Related]
9. High-intensity intravenous cyclophosphamide and cisplatin, interim surgical debulking, and intraperitoneal cisplatin in advanced ovarian carcinoma: a pilot trial with ten-year follow-up. Shapiro F; Schneider J; Markman M; Reichman BS; Venkatraman E; Barakat R; Almadrones L; Spriggs D Gynecol Oncol; 1997 Oct; 67(1):39-45. PubMed ID: 9345354 [TBL] [Abstract][Full Text] [Related]
10. Medical therapy of advanced malignant epithelial tumours of the ovary. Colombo N; Parma G; Bocciolone L; Franchi D; Sideri M; Maggioni A Forum (Genova); 2000; 10(4):323-32. PubMed ID: 11535983 [TBL] [Abstract][Full Text] [Related]
11. Cyclophosphamide and cisplatin versus paclitaxel and cisplatin: a phase III randomized trial in patients with suboptimal stage III/IV ovarian cancer (from the Gynecologic Oncology Group). McGuire WP; Hoskins WJ; Brady MF; Kucera PR; Partridge EE; Look KY; Clarke-Pearson DL; Davidson M Semin Oncol; 1996 Oct; 23(5 Suppl 12):40-7. PubMed ID: 8941409 [TBL] [Abstract][Full Text] [Related]
12. Repetitive high-dose topotecan, carboplatin, and paclitaxel with peripheral blood progenitor cell support in previously untreated ovarian cancer: results of a Phase I study. Prince HM; Rischin D; Quinn M; Allen D; Planner R; Neesham D; Gates P; Davison J Gynecol Oncol; 2001 May; 81(2):216-24. PubMed ID: 11330952 [TBL] [Abstract][Full Text] [Related]
13. Combined cisplatin and carboplatin chemotherapy for treatment of advanced epithelial ovarian cancer. Gershenson DM; Morris M; Burke TW; Levenback C; Kavanagh JJ; Fromm GL; Silva EG; Warner D; Wharton JT Gynecol Oncol; 1995 Sep; 58(3):349-55. PubMed ID: 7672700 [TBL] [Abstract][Full Text] [Related]
14. Addition of epirubicin as a third drug to carboplatin-paclitaxel in first-line treatment of advanced ovarian cancer: a prospectively randomized gynecologic cancer intergroup trial by the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group and the Groupe d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens. du Bois A; Weber B; Rochon J; Meier W; Goupil A; Olbricht S; Barats JC; Kuhn W; Orfeuvre H; Wagner U; Richter B; Lueck HJ; Pfisterer J; Costa S; Schroeder W; Kimmig R; Pujade-Lauraine E; ; ; J Clin Oncol; 2006 Mar; 24(7):1127-35. PubMed ID: 16505432 [TBL] [Abstract][Full Text] [Related]
15. Phase III trial of high-dose sequential chemotherapy with peripheral blood stem cell support compared with standard dose chemotherapy for first-line treatment of advanced ovarian cancer: intergroup trial of the AGO-Ovar/AIO and EBMT. Möbus V; Wandt H; Frickhofen N; Bengala C; Champion K; Kimmig R; Ostermann H; Hinke A; Ledermann JA; ; J Clin Oncol; 2007 Sep; 25(27):4187-93. PubMed ID: 17698804 [TBL] [Abstract][Full Text] [Related]
17. Phase III trial of observation versus six courses of paclitaxel in patients with advanced epithelial ovarian cancer in complete response after six courses of paclitaxel/platinum-based chemotherapy: final results of the After-6 protocol 1. Pecorelli S; Favalli G; Gadducci A; Katsaros D; Panici PB; Carpi A; Scambia G; Ballardini M; Nanni O; Conte P; J Clin Oncol; 2009 Oct; 27(28):4642-8. PubMed ID: 19704064 [TBL] [Abstract][Full Text] [Related]
18. Randomized study of the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group comparing quality of life in patients with ovarian cancer treated with cisplatin/paclitaxel versus carboplatin/paclitaxel. Greimel ER; Bjelic-Radisic V; Pfisterer J; Hilpert F; Daghofer F; du Bois A; J Clin Oncol; 2006 Feb; 24(4):579-86. PubMed ID: 16446330 [TBL] [Abstract][Full Text] [Related]
19. Analysis of treatment failures and survival of patients with fallopian tube carcinoma: a cooperation task force (CTF) study. Gadducci A; Landoni F; Sartori E; Maggino T; Zola P; Gabriele A; Rossi R; Cosio S; Fanucchi A; Tisi G Gynecol Oncol; 2001 May; 81(2):150-9. PubMed ID: 11330942 [TBL] [Abstract][Full Text] [Related]
20. Impact of adjuvant chemotherapy and surgical staging in early-stage ovarian carcinoma: European Organisation for Research and Treatment of Cancer-Adjuvant ChemoTherapy in Ovarian Neoplasm trial. Trimbos JB; Vergote I; Bolis G; Vermorken JB; Mangioni C; Madronal C; Franchi M; Tateo S; Zanetta G; Scarfone G; Giurgea L; Timmers P; Coens C; Pecorelli S; J Natl Cancer Inst; 2003 Jan; 95(2):113-25. PubMed ID: 12529344 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]